Search for: "Genentech Inc." Results 161 - 180 of 469
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 Feb 2023, 4:00 pm
While we defer to the district court’s assessment of the average time to trial data, see Planned Parenthood, 52 F.4th at 631; In re Genentech, Inc., 566 F.3d 1338, 1347 (Fed. [read post]
1 May 2008, 4:05 am
 And the Federal Circuit explicitly rejected Tempco in Genentech, Inc. v. [read post]
9 May 2013, 6:34 pm by Mary Dwyer
Genentech, Inc., the licensee has the burden to prove that its products do not infringe the patent, or whether (as is the case in all other patent litigation, including other declaratory judgment actions), the patentee must prove infringement. [read post]
26 Jun 2017, 1:58 pm by Tom Lamb
An insightful article by reported Charles Piller, "Failure to warn: Hundreds died while taking an arthritis drug, but nobody alerted patients"(subscription required), published June 5, 2017 online by STAT, put the spotlight on some serious but little-known side effects associated with this medicine from Genentech, Inc. [read post]
12 May 2009, 2:44 am
The drug was developed by OSI Pharmaceuticals Inc. and is sold by Genentech. [read post]
1 Jul 2015, 9:11 am by David Jensen
Millan and Bonneville both were promoted from within the organization.Ramona Doyle, Rhodes Project photoDoyle comes from Genentech. [read post]
11 Jun 2019, 7:43 am by Dennis Crouch
[Watch Here] Today’s witnesses are primarily business leaders and in-house attorneys for large IP-focused businesses: Panel I Manny Schecter, Chief Patent Counsel at IBM Laurie Self, Senior Vice-President and Counsel at Qualcomm Byron Holz, Senior Counsel at Nokia Kim Chotkowski, VP at InterDigital Sean Reilly, Associate General Counsel at The Clearing House Payments Company Panel II Laurie Hill, VP for IP at Genentech Sean George, CEO at Invitae… [read post]
19 May 2021, 10:40 am by Dennis Crouch
Genentech, Inc., 549 U.S. 118 (2007); Cardinal Chem. [read post]
23 Mar 2012, 4:00 am by tracey
& Anor [2012] EWHC 716 (Ch) (22 March 2012) Rohl v Bickland Ltd [2012] EWHC 706 (Ch) (22 March 2012) High Court (Patents Court) Teva UK Ltd & Ors v Astrazeneca AB [2012] EWHC 655 (Pat) (22 March 2012) Regeneron Pharmacueticals Inc v Genentech Inc [2012] EWHC 657 (Pat) (22 March 2012) Source: www.bailii.org [read post]
25 Jun 2020, 9:59 am by Ben Vernia
As Regeneron’s former Chief Financial Officer put it, Lucentis patients were “Genentech’s problem. [read post]